AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22261439
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of B vitamin supplementation and exercise training for 6 weeks
Trial: 20437565
Drug: Memantine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (40 mg/day)
Trial: 10630348
Drug: Neural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural therapy (injection of local anesthetic without adrenaline into specific trigger points)
Trial: 8520623
Drug: Norethindrone (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone (low-dose therapy)
Trial: 2239806
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 100 mg/m2 daily by constant infusion for 5 days
Trial: 2239806
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 150 mg/m2 daily by constant infusion for 5 days
Trial: 2239806
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 200 mg/m2 daily by constant infusion for 5 days
Trial: 2239806
Drug: Mitoxantrone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone plus etoposide (various doses)
Trial: 28303900
Drug: Amphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (20 mg)
Trial: 26235968
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg/day) for 6 months
Trial: 26235968
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (25 mg daily) for 6 months
Trial: 26235968
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin E and clomiphene citrate for 6 months
Trial: 3139285
Drug: 5-day rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day rIL-2 bolus (10^5 units/kg every 8 hours) followed by LAK cell infusion
Trial: 3139285
Drug: 3-day rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day rIL-2 prime and 6-day continuous infusion rIL-2 (3 x 10^6 units/m2/day) with LAK cell infusion
Trial: 3139285
Drug: LAK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAK cell infusion
Trial: 23464951
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy with a licensed therapist
Trial: 21439528
Drug: Very-low-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose heparin (2,000 IU)
Trial: 21439528
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5,000 IU)
Trial: 18192671
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.1 mg triptorelin) administered 6 days after ICSI
Trial: 18192671
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 6 days after ICSI
Trial: 16611715
Drug: eGFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <60 ml/min per 1.73 m²
Trial: 16611715
Drug: eGFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <60 ml/min per 1.73 m² and >=2+ proteinuria
Trial: 1740861
Drug: Educational memorandum
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational memorandum outlining vaccine indications
Trial: 1740861
Drug: Vaccine offered
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine offered directly in clinics and conferences
Trial: 6430053
Drug: Low-dose NTG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NTG patches (n = 7)
Trial: 6430053
Drug: Maximally tolerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximally tolerated NTG patches (first type, n = 8, mean NTG dose delivered 25 mg)
Trial: 6430053
Drug: Maximally tolerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximally tolerated NTG patches (second type, n = 5, mean NTG dose delivered 22 mg)
Trial: 6430053
Drug: Sublingual NTG
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual NTG (positive control)
Trial: 27447428
Drug: VEL015 (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEL015 (sodium selenate) 10 mg tds (n=20)
Trial: 24517114
Drug: Teduglutide 4
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 4 mg once daily for 10 days
Trial: 20561625
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g glucose control
Trial: 17318839
Drug: Sumanirole, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumanirole, 1 to 16 mg/day
Trial: 17318839
Drug: Ropinirole, 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole, 0.75 to 24 mg/day
Trial: 15680855
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch solution
Trial: 10839469
Drug: Reboxetine 2-8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 2-8 mg/day
Trial: 1617494
Drug: Disodium monofluorophosphate-calcium
RxNorm normalized name: calcium monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium monofluorophosphate-calcium carbonate (MFP-Ca) 100 mg with breakfast
Trial: 1617494
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) 25 mg fasting
Trial: 6393670
Drug: NPH biosynthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH biosynthetic human insulin
Trial: 6393670
Drug: NPH pork
RxNorm normalized name: Iletin II NPH Pork
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH pork insulin
Trial: 31834152
Drug: Office-based vergence/accommodative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vergence/accommodative therapy for intermittent exotropia (60 minutes once per week for 12 weeks)
Trial: 31834152
Drug: Office-based vergence/accommodative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vergence/accommodative therapy for intermittent exotropia
Trial: 26896263
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with Drug-Eluting Stents (DES)
Trial: 24658221
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol (0.6 g/kg for females, 0.7 g/kg for males)
Trial: 24658221
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ethanol (1.2 g/kg for females, 1.4 g/kg for males)
Trial: 15740541
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg
Trial: 11919405
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous sodium ferric gluconate (6.25-21.3 mg in every hemodialysis session)
Trial: 11919405
Drug: Intermittent sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sodium ferric gluconate (62.5 mg every 1-4 weeks)
Trial: 7717630
Drug: Nucleus 22
RxNorm normalized name: SUS SCROFA THALAMUS LATERAL GENICULATE NUCLEUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus 22 cochlear implant
Trial: 7717630
Drug: Smith &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smith & Nephew Richards Ineraid cochlear implant
Trial: 7717630
Drug: 3M/Vienna cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3M/Vienna cochlear implant
Trial: 23043926
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention combined with Tagamet 800 mg per evening p.o.
Trial: 23043926
Drug: Tagamet 800
RxNorm normalized name: Tagamet 800mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagamet 800 mg per evening p.o.
Trial: 19938712
Drug: Modified gelatin
RxNorm normalized name: modified fluid gelatins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified gelatin solution ‐ Gelofusin
Trial: 11588740
Drug: Inpatient rehabilitation
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient rehabilitation (therapeutical and neuromuscular exercises with occupational therapy with professional supervision)
Trial: 9848512
Drug: Soy supplementation
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplementation (60-g soy supplement containing 45 mg isoflavones) taken daily for 14 days
Trial: 8079970
Drug: Dialysate magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate magnesium concentration of 0 mg/dL
Trial: 8079970
Drug: Dialysate magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate magnesium concentration of 0.6 mg/dL
Trial: 8079970
Drug: Dialysate magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate magnesium concentration of 1.8 mg/dL
Trial: 2589846
Drug: Zidovudine syrup
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine syrup
Trial: 2589846
Drug: Zidovudine solution
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine solution
Trial: 2589846
Drug: Zidovudine capsule
RxNorm normalized name: Zidovudine Capsules
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine capsule
Trial: 1039629
Drug: 50-minute class
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-minute class in acupuncture and Chinese medicine
Trial: 28692467
Drug: Bolus-plus-infusion group
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus-plus-infusion group (tranexamic acid 1g infusion for 8 hours)
Trial: 28692467
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (placebo infusion for 8 hours)
Trial: 25941995
Drug: Sham insole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham insole treatment
Trial: 21316752
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 mg on day 1 to 16 mg on days 3 to 7)
Trial: 14610122
Drug: Topiramate at
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate at low plasma level (6 micromol/L [2 mg/L])
Trial: 14610122
Drug: Topiramate at
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate at medium plasma level (31 micromol/L [10.5 mg/L])
Trial: 14610122
Drug: Topiramate at
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate at high plasma level (56 micromol/L [19 mg/L])
Trial: 10696124
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy leading to complete necrosis (CNWT)
Trial: 8730245
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 750 mg t.d.s. for 2 weeks
Trial: 8730245
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg t.d.s. plus amoxycillin 750 mg t.d.s. for 2 weeks
Trial: 1420747
Drug: High enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High enzyme preparation ('Pancrease HL', Cilag)
Trial: 1420747
Drug: Standard pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pancreatic enzyme supplement ('Creon', Duphar)
Trial: 12355035
Drug: Intravenous blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous blockade of the glycoprotein IIb/IIIa receptor
Trial: 12355035
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment duration
Trial: 12355035
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of glycoprotein IIb/IIIa inhibitor
Trial: 7642758
Drug: Non-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment control groups
Trial: 2694315
Drug: 100 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg/kg of ivermectin
Trial: 2694315
Drug: 150 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mcg/kg of ivermectin
Trial: 2694315
Drug: 200 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg/kg of ivermectin
Trial: 25917009
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Trial: 25917009
Drug: Sleep Hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Hygiene (SH) control condition combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Trial: 20940691
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens (Permixon®) 320 mg daily for two months prior to surgery (G1)
Trial: 10715308
Drug: Tirapazamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirapazamine plus cisplatin (390 mg/m2 infused over 2 hours followed 1 hour later by cisplatin 75 mg/m2 over 1 hour, every 3 weeks for a maximum of eight cycles)
Trial: 10715308
Drug: Cisplatin alone
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin alone (75 mg/m2, every 3 weeks for a maximum of eight cycles)
Trial: 1539786
Drug: Papaveretum followed
RxNorm normalized name: papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum followed by paracetamol plus dextropropoxyphene orally
Trial: 3904205
Drug: Gamma therapy
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma therapy with total focal dose of 90-120 Gy
Trial: 29175357
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sodium nitrite (1 or 9.6mg)
Trial: 29175357
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sodium nitrite (9.6mg)
Trial: 16000283
Drug: 18F‐FDG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F‐FDG PET after the first cycle of chemotherapy
Trial: 16000283
Drug: 18F‐FDG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F‐FDG PET after the second cycle of chemotherapy
Trial: 16000283
Drug: 18F‐FDG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F‐FDG PET for nonresponding lesions after the first cycle of chemotherapy
Trial: 16000283
Drug: 18F‐FDG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F‐FDG PET for nonresponding lesions after the second cycle of chemotherapy
Trial: 12432319
Drug: Opioid analgesics
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesics pro re nata (as needed)
Trial: 12432319
Drug: Regularly scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly scheduled opioid analgesics
Trial: 8565248
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal therapy (group 1)
Trial: 25502841
Drug: Remimazolam (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.10 mg/kg)
Trial: 25502841
Drug: Remimazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.15 mg/kg)
Trial: 25502841
Drug: Remimazolam (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (0.20 mg/kg)
Trial: 25502841
Drug: Remimazolam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (all doses)
Trial: 21227735
Drug: 2 weekly
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weekly replacement lenses
Trial: 21227735
Drug: Monthly replacement
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly replacement lenses
Trial: 12390609
Drug: Multidisciplinary management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary management program (neurologist and physical therapist intake and discharge, 18 group-supervised exercise therapy sessions, 2 group stress management and relaxation therapy lectures, 1 group dietary lecture, and 2 massage therapy sessions)
Trial: 9749162
Drug: Additional prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional prescription of beta-blocker
Trial: 9749162
Drug: Additional prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional prescription of ACE-inhibitor
Trial: 8156459
Drug: Spiramycin, 1,500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin, 1,500,000 international units, twice per day (IU, bid) for 14 days
Trial: 8156459
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (visually identical)
Trial: 2459514
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg once or twice daily)
Trial: 2459514
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg twice daily)
Trial: 26572551
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (group sessions)
Trial: 25216143
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed level with the buccal crest (Group 0)
Trial: 25216143
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 1 mm apical to the buccal aspect of the alveolar crest (Group 1)
Trial: 25216143
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 2 mm apical to the buccal aspect of the alveolar crest (Group 2)
Trial: 21035616
Drug: PMT-S (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMT-S (single instructional workshop followed by self-administration)
Trial: 10206081
Drug: MPV-2213ad 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPV-2213ad 0.3 mg
Trial: 10206081
Drug: MPV-2213ad 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPV-2213ad 3 mg
Trial: 10206081
Drug: MPV-2213ad 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPV-2213ad 100 mg
Trial: 729626
Drug: Indoramin 50
RxNorm normalized name: indoramin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 50 mg t.i.d.
Trial: 31138224
Drug: Duloxetine 30/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30/60 mg once daily (QD)
Trial: 31138224
Drug: Duloxetine 30/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30/60 mg QD
Trial: 25380326
Drug: CO2 angiography-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 angiography-guided endovascular therapy (EVT)
Trial: 16960168
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of black (0.1 g), green (0.1 g), and mulberry (1.0 g) teas with carbohydrate-containing meal (50 g carbohydrate as white rice, 10 g butter, and 0.2 g [13C]triolein)
Trial: 16960168
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of black, green, and mulberry teas with lipid-containing meal (30 g olive oil and 0.2 g [13C]triolein)
Trial: 12848875
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of AMI-I (GCT)
Trial: 10783989
Drug: Radiotherapy (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (high-dose radiation)
Trial: 10783989
Drug: Chemoradiation (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation (combination of chemotherapy and radiation)
Trial: 10783989
Drug: Multi-modality therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modality therapy (combination of treatments)
Trial: 8796164
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with 2% prilocaine